rethinkTHC Search
Menu
Study breakdown

A practical guide for clinicians on cannabis use by IBD patients, including clinical vignettes

ReviewPreliminary evidence
The takeaway

While cannabis may help manage some IBD symptoms, it has not been proven to reduce inflammation, and clinicians should be aware of dosing inconsistencies, dependence risks, and cannabinoid hyperemesis syndrome.

Gastroenterologists, IBD patients considering cannabis, primary care providers managing IBD

Cannabis has not been proven to reduce IBD inflammation

What the researchers found

Cannabis has gained popularity for IBD symptom management but has not been proven to reduce inflammation or correct underlying disease processes. Key concerns include dosing inconsistencies across products, risk of dependence, and cannabinoid hyperemesis syndrome.

Why it matters

As more IBD patients turn to cannabis, clinicians need practical guidance on discussing its potential benefits and limitations, especially distinguishing symptom relief from disease modification.

The numbers in context

15 U.S. states regulate adult cannabis use; 36 states for medical use; cannabis has not been proven to help with IBD inflammation

How the study worked

Review article summarizing current research on cannabis and IBD, supplemented with clinical vignettes illustrating practical considerations for clinicians.

What this study cannot tell us

Narrative review without systematic methodology. Clinical vignettes illustrate but do not provide evidence. Limited by the small number of available clinical studies on cannabis for IBD.

How to read the evidence

Narrative review with clinical vignettes for practical guidance

When this study was published

Published in 2021. Cannabis use among IBD patients continues to increase as access expands.

The bigger picture

The disconnect between patient enthusiasm for cannabis and the limited evidence for its efficacy in IBD represents a common pattern across many chronic conditions where patients seek alternatives to conventional treatment.

Questions still open

  • Should gastroenterologists proactively discuss cannabis with IBD patients? How should clinicians monitor patients who use cannabis alongside IBD medications? What standardized guidance can be developed for this common clinical scenario?

Common questions

Should IBD patients use cannabis?
Cannabis may help manage some symptoms like pain, but has not been proven to reduce the inflammation underlying IBD. Patients should discuss potential benefits and risks with their gastroenterologist.
What risks should IBD patients know about cannabis?
Key concerns include dosing inconsistencies between products, risk of dependence with chronic use, and cannabinoid hyperemesis syndrome, which paradoxically causes severe vomiting in some chronic users.

Read the original research

Inflammatory Bowel Disease and Cannabis: A Practical Approach for Clinicians.

Advances in therapy, 38(7), 4152-4161

Citation

Buckley, Megan C; Kumar, Anand; Swaminath, Arun. (2021). Inflammatory Bowel Disease and Cannabis: A Practical Approach for Clinicians.. Advances in therapy, 38(7), 4152-4161. https://doi.org/10.1007/s12325-021-01805-8

Explore the wider topic